Shots: The company initiates P-II KET-LID clinical trial to evaluate the safety, efficacy, and PK of Ketamine (sub-anesthetic, IV) vs PBO in patients with LID associated with PD. The patient […]readmore
Tags : Parkinson’s Disease
Shots: Caraway to receive ~$267M including $17M up front in cash and remaining as option payment & milestones and is eligible for additional regulatory and commercial milestones along with royalties […]readmore
Shots: STADA acquires Lobsar and its innovative therapy to foster its footprints in specialty pharmaceuticals. The acquisition complements STADA’s portfolio and expertise in the treatment of late-stage Parkinson’s disease With […]readmore
Shots: Denali to receive $560M up front, $465M as equity investment at a price of $34.94/ share, representing 11.2% of Denali’s Pro-forma outstanding stock along with $1.125B as milestones. The […]readmore
Shots: Oxford Biomedica will manufacture GMP batches for Axovant to support the ongoing and future clinical development of AXO-Lenti-PD (formerly OXB-102) to treat mod. to sev. PD based on Oxford’s […]readmore
Shots: The US FDA has granted approval to Nourianz for use as an add-on treatment to levodopa/carbidopa and is based on clinical studies assessing Nourianz vs PBO in PD patients […]readmore
Shots: The DBS system with the Vercise Cartesia Directional Lead is evaluated in INTREPID study which demonstrated that patients treated with the Vercise System resulted in 48% improvement in motor […]readmore
Shots: The agreement collaborates C4XD’s Taxonomy3 (target identification platform) with PhoreMost’s SITESEEKER (screening platform) to accelerate drug discovery initially focusing on Parkinson’s disease with expected profit sharing by both the […]readmore
Shots: Hisamitsu to receive upfront, milestone based on the regulatory approval and royalties on sales of product. Kyowa Kirin to get exclusive commercialization rights for Hisamitsu’s HP-3000, post marketing approval […]readmore
Shots: The ongoing AXO-Lenti-PD (also known OXB-102) study evaluates efficacy, safety, tolerability and measuring motor function in patients with PD. The closure of initial results from study is expected in […]readmore